TALINE KHOUKAZ: Open Payments
NPI 1639368103 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,262 in 42 payments from 14 companies in 2025. Trend: 2023 $917 · 2024 $1,151 · 2025 $1,262
Food & beverage: $1,262
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 12 | $263 |
| Incyte Corporation | 3 | $150 |
| GENZYME CORPORATION | 5 | $145 |
| Astellas Pharma US Inc | 1 | $135 |
| BeOne Medicines USA, Inc. | 5 | $117 |
| Syndax Pharmaceuticals, Inc. | 1 | $103 |
| E.R. Squibb & Sons, L.L.C. | 4 | $82 |
| Gilead Sciences, Inc. | 3 | $58 |
| Daiichi Sankyo Inc. | 2 | $51 |
| SOBI, INC | 1 | $43 |
Products named: CALQUENCE, ZYNYZ, Vyloy, BRUKINSA, SARCLISA, OPDIVO, Trodelvy, DATROWAY.
Industry payments across CA — which companies pay providers there.
